This project will support the establishment of an innovation research and development (R&D) centre and a commercial scale, good manufacturing practices (GMP) manufacturing facility in Edmonton, Albert...
Entos Pharmaceuticals Inc.
14 records totalling $88,806,102.07 CAD, from official Government of Canada open data.
Embed this chart
Lobbying registry — possible match matched by name
An organization with this name appears in 38 federal lobbying registrations (0 currently active), between 2020 and 2026.
946789-367391-15 946789-367391-14 946789-367391-13
Matched automatically by organization name; a different organization with the same name is possible. The Registry of Lobbyists is the authoritative source. Lobbying is legal and regulated — this is context, not an allegation.
By department
| Innovation, Science and Economic Development Canada | $62,000,000 | 1 record |
| National Research Council Canada | $26,798,300 | 12 records |
| Global Affairs Canada | $7,802 | 1 record |
Records
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine...
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c biva...
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine...
Seasonal and pandemic influenza continue to pose substantial threats to public health and highly pathogenic strains such as H5N1 carry the potential for devastating outbreaks. The Firm proposes to dev...
In partnership with a large Multinational Pharmaceutical Partner, the Firm will evaluate the safety and effectiveness of its Fusogenix formulations optimized for delivery of genetic medicines to the t...
As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimize...
The goal of this project is to establish a method to synthesize Fusogenix DNA lipid nanoparticles using a single step manufacturing process. To achieve this, we will evaluate a number of methods to in...
This project utilizes the Entos Fusogenix DNA delivery platform to rapidly develop, validate, manufacture and deploy countermeasures to protect the majority of the Canadian population from SARS-CoV-2...
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation o...
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research...